In a number of experimental systems, the early stage of the apoptotic process, i.e., the stage that precedes nuclear disintegration, is characterized by the breakdown of the inner mitochondrial transmembrane potential (Aqtm). This A~ m disruption is mediated by the opening of permeability transition (PT) pores and appears to be critical for the apoptotic cascade, since it is directly regulated by Bcl-2 and since mitochondria induced to undergo PT in vitro become capable of inducing nuclear chromatinolysis in a cell-free system ofapoptosis. Here, we addressed the question of which apoptotic events are secondary to mitochondrial PT. We tested the effect of a specific inhibitor of PT, bongkrekic acid (BA), a ligand of the mitochondrial adenine nucleotide translocator, on a prototypic model of apoptosis: glucocorticoid-induced thymocyte death. In addition to abolishing the apoptotic A~,n disruption, BA prevents a number of phenomena linked to apoptosis: depletion ofnonoxidized glutathione, generation of reactive oxygen species, translocation of NFKB, exposure of phosphatidylserine residues on the outer plasma membrane, cytoplasmic vacuolization, chromatin condensation, and oligonucleosomal DNA fragmentation. BA is also an efficient inhibitor of p53-dependent thymocyte apoptosis induced by DNA damage. These data suggest that a number of apoptotic phenomena are secondary to PT. In addition, we present data indicating that apoptotic Aqr,, disruption is secondary to transcriptional events. These data connect the PT control point to the p53-and ICE/ Ced 3-regulated control points of apoptosis and place PT upstream of nuclear and plasma membrane features of PCD.
I n many models of apoptosis induction, disruption of the mitochondrial transmembrane potential (A~m) is observed shortly before other features ofapoptosis (generation of reactive oxygen species, plasma membrane perturbations, chromatin condensation, and DNA fragmentation) become detectable. This applies to very different cell types and protocols ofapoptosis induction (1) (2) (3) (4) (5) . A~ m disruption marks a point-of-no-return of the apoptotic cascade (3), and mitochondria or mitochondrial products induce chromatin condensation and DNA fragmentation in cell-free systems ofapoptosis (5) (6) (7) . We have recently shown that in a cell-free system, mitochondria only become proapoptotic. when they undergo permeability transition (PT; 5), a phenomenon that is also thought to accout for A~,~ disruption in intact cells (8) . Intriguingly, Bcl-2 is an inhibitor of PT, both in isolated mitochondria and in cells (5, 8) , underlin-P. Marchetti and M. Castedo contributed equally to this work.
ing that PT may indeed constitute a central checkpoint of the apoptotic cascade. In addition to the putative PT/Bcl-2 checkpoint, it is currently assumed that the ICE/Ced3 family of proteases controls a further apoptotic checkpoint (reviewed in 9). Thus far, the hierarchy between these two hypothetical control points has remained obscure (10) .
Although published data establish that end-stage apoptosis is chronologically secondary to PT-mediated A~ m disruption (1-4), they do not clarify which features ofapoptosis are linked to PT in a cause-effect relationship. To resolve this problem, we have studied the effects of PT inhibition on the apoptotic cascade in a prototypic model of apoptosis, namely the dexamethasone (DEX)-induced death of thymocytes (11). Recently, we have observed that the substance that most closely mimics the PT-inhibitory effect of Bcl-2, both in cells and in isolated mitochondria, is bongkrekic acid (BA; 5). BA is a specific ligand of a protein located in the inner mitochondrial membrane, the adenine nucleotide translocator (ANT; 12, 13). The ANT belongs to the structures of the mitochondrial membrane that may participate in the formation of PT pores, probably via interaction with proteins from the outer membrane (13) , and BA is known to affect the molecular conformation of the ANT, thereby reducing the probability of PT pore gating (12, 13) . As does Bcl-2, BA inhibits PT pore opening in response to prooxidants, protonophores, and the ANT ligand atractyloside, but fails to interfere with PT induction by Ca 2 § and chemical thiol crossqinking (5) . While inhibiting PT, both BA and Bcl-2 prevent the release of (a) proapoptotic protein(s) from mitochondria (5). Thus, BA mimics the mitochondrial effects of Bcl-2.
Here, we tested the effect of BA on cells undergoing apoptosis rather than on isolated mitochondria. We show that via its PT-inhibitory (= A~,~,-stabilizing) effect, BA inhibits all major cytoplasmic, plasma membrane, and nuclear features ofapoptosis. These data establish PT a's a central event of the apoptotic cascade. In addition, we addressed the question as to whether proteases from the ICE/Ced3 family act upstream of mitochondria. Indeed, inhibition of such proteases prevents the apoptotic ARt dissipation, suggesting that they act on a level that is hierarchically superior to the Bcl-2/PT control point of apoptosis.
Materials and Methods
Culture Conditions and Apoptosis Induction. Thymocytes were obtained from female BALB/c mice (6-10 wk old) and were cultured in the absence or presence ofdexamethasone (DEX; 1 IxM), protoporphyrin IX (PPIX; 30 buM), cycloheximide (35 buM), actinomycin D (3 txM), the protease inhibitor N-tosyl-t-lysyl chloromethylketone ([TLCK] 50 txM; all reagents from Sigma hnmunochemicals, St. Louis, MO), the inhibitor of interleukin-1-converting enzyme (ICE)-like proteases N-benzyloxycarbonylVal-Ala-Asp.fluoromethylketone (Z-VAD.fmk; Enzyme Systems Products, Dublin, CA), R.U-38486 (10 txM; kindly provided by l<oussel Uclaf, P, omainville, France), and/or bongkrekic acid (BA), purified as described (14) and kindly provided by Dr. Duine (Delft University of Technology, Delft, The Netherlands). The standard dose of BA was 50 IxM during 4-12 h, followed by assessment of mitochondrial or nuclear parameters of apoptosis. Alternatively, apoptosis was induced in thymocytes from C57B1/6 mice that were rendered deficient for p53 by homologous recombination (kindly provided by F. l:(advanyi, Institut Curie, Paris, France). Thymocytes from p53 -/-animals (15) or p53 +/+ littem~ates were irradiated (10 Gy) or cultured in the presence of etoposide (10 I~M; Sigma) or DEX (10 buM).
Cytofluorometric Analysis of Mitochondrial Transmembrane Potentials, Reactive
Oxygen Species, and Nonoxidized Glutathione. To measure A~,,, and superoxide anion generation, cells (5 X 10S/ml) were incubated with 3,3'-dihexyloxacarbocyanine iodide (DiOC~,(3), 40 nM in PBS; Molecular Probes, Inc., Eugene, OIL) (3) and dihydroethidine (HE; 2 I~M) (8) for 15 min at 37~ followed by analysis on an Epics cytofluorometer (Coulter Corp., Hialeah, FL) while gating on all cells. Levels of intracellular thiols (mainly nonoxidized glutathione) were quantitated using monochlorobimane (MCB, 40 buM; Molecular Probes) as a specific probe (16) . As a negative control, cells were incubated during 30 min with the glutathione-depleting agent N-ethylmaleimide (50 txM; Sigma).
Analysis of Nuclear DNA Loss, Cell Viability, Phosphatidylserine Exposure, and Electron Microscopy. The frequency of subdiploid cells was determined by propidium iodine (PI) staining of ethanol-permeabilized cells. The apoptosis-associated increase in membrane permeability for propidium iodine was assessed as described (3) . An FITC-annexin V conjugate (1/400 dilution, I bug/ml, 15 rain at 4~ Brand Applications, Maastricht, The Netherlands) with high affinity for PS was used for the assessment of aberrant PS exposure (17) . Cells were labeled simultaneously with ethidium bromide (EthBr; 200 ng/ml) and FITC-annexin V, and data are shown for viable (EthBr-) cells. DNA fragmentation (10 ~' cells/lane) was determined by horizontal agarose gel electrophoresis (3). For electron microscopy, cells were prepared by glutaraldehyde fixation (2.5% in 0.1 M cacodylate buffer, pH 7.2, 2 h at room temperature), washed twice in cacodylate buffer, fixed in 2% OsO4, encapsulated in agar, dehydrated in ethanol, and embedded in Epon. Ultrathin sections were floated successively on uranyl acetate and lead citrate solutions before being observed in an AEI6B electron microscope at 60 kV.
Determination OfNFKB Translocation. Nuclear extracts were prepared according to standard protocols (18) . For the gel retardation assay, nuclear proteins (30 pug) were preincubated with 10 lug salmon sperm DNA (GIBCO BILL, Cergy, France) for 15 rain on ice before addition of the -~2p-labeled NFKB oligonucleotide probe (5'ACAAGGGACTTTCCGCTGGGGACTTTCCAG 3'; 2-10 X t0 s dpm/ng). Protein-bound oligonucleotide was separated from the free probe using a spin column (GIBCO BRL). 2 bul of 0.1% bromophenol blue and 25 bul of the mixture were loaded onto 6% polyacrylamide gel. Electrophoresis was performed during 100 rain at 150 V in tris-borate EDTA buffer, followed by autoradiography. Nuclear extracts from THP1 cells that were stimulated during 60 min with 20 ng/ml of LPS served as positive controls. As a specifici W control, nuclear extracts were incubated in a 1,000-fold excess of unlabeled NFKB oligonucleotide probe.
Results and Discussion

BA, an Inhibitor of Mitochondrial Permeability Transition, Suppresses the DEX-induced Axlz Reduction and Apoptosis.
BA is known to affect the molecular conformation of the ANT, thereby reducing the probability of PT pore gating (12, 13) . We have used this PT inhibitor to address the significance of PT in thymocyte apoptosis. As shown in Fig. 1 A, BA inhibits the DEX-induced A~ m loss. Concomitantly, BA prevents the I)EX-induced oligonucleosomal DNA fragmentation ( Fig. 1 /3 ) and nuclear DNA loss ( Fig.  1 C-) , indicating that inhibition of PT can prevent the nuclear manifestations of apoptosis in intact cells. Transmission electron microscopy revealed that BA, when added together with DEX, reduced significantly the number of cells showing chromatin condensation, as compared to cells treated with DEX alone (Fig. 1 E) . The dose of BA required to inhibit chromatinolysis is the same as that which is necessary to prevent the DEX-induced AxIr,1 reduction (Fig. I D) , underscoring the functional linkage between both phenomena. In conclusion, BA inhibits the DEXinduced manifestations of apoptosis, both at the level of mitochondria and at the level of chromatin structure.
Effect of BA on Metabolic and Plasma Membrane Man!~'stations qfApoptosis.
In addition to inhibiting nuclear apop- (Fig. 2 A) (16) , as well as the DEX-triggered hypergeneration of superoxide anions (Fig.  1 A) . This latter result is coherent with the AXtrm-stabilizing effect of BA, since superoxide radicals are formed on the uncoupled respiratory chain, after PT has occurred (8) . In accord with its effect on the cellular redox potential, BA prevents the DEX-stimulated NFKB translocation (Fig. 2 B) . BA also abolishes the membrane exposure of phosphatidylserine residues (Fig. 2 C) provoked by DEX, and thus prevents one of the principal membrane features of early apoptosis (17, 19) . BA also prevents the later loss of cell viability affecting DEX-treated thymocytes (Fig. 2 D) and abolishes cytoplasmic features of apoptosis such as vacuolization (Fig. 1 E) . In conclusion, prevention of apoptosisassociated PT by BA does not only impede the A~ m reduction, but also prevents apoptotic changes at the level of the cytoplasm and the plasma membrane.
BA Does Not Act by Quenching Early Activation Signals.
BA is effective in inhibiting chromatinolysis, even when it is added up to 2 h after D E X addition (Fig. 3 A) , i.e., at a time point at which the glucocorticoid receptor antagonist R U 3 8 4 8 6 fails to interfere with apoptosis, indicating that BA does not act by quenching of early glucocorticoid re- ceptor-mediated activation signals. Moreover, BA does not inhibit apoptosis via inhibition with macromolecular synthesis. This is suggested by the fact that BA effectively prevents the Aqt m disruption and chrornatinolysis of thyrnocytes responding to PPIX (Fig. 3 B) , a substance that induces PT directly by acting on a mitochondrial receptor (20) . PPIX-induced apoptosis is not affected by inhibitors of RNA or protein synthesis, yet is fully antagonized by BA (Fig. 3 B) . Thus, a mode of apoptosis induction that does not require macromolecule synthesis is efficiently antagonized by BA.
Dissociation between BA-modulated and p53-mediated Apoptotic Control. To determine the putative relationship between the p53-rnediated control and the mode of action of BA, we studied whether BA would conserve its apoptosisinhibitory effect in thyrnocytes from mice hornozygous for deletion mutations of the antioncogene p53 (2o53-/-). As shown in Fig. 4 A, in response to irradiation and the topoisomerase II inhibitor etoposide (21, 22) . Such p53 -/-thymocytes also fail to exhibit signs of irradiation-or etoposide-induced A~ m reduction, suggesting that p53 controls a common event upstream of both apoptotic A~n~ dissipation and of nuclear apoptosis. Addition of BA to p53 +/+ thymocytes prevents both the Axl2" m reduction and the nuclear signs of apoptosis induced by irradiation or etoposide (Fig. 4 A) . Moreover, BA prevents the DEX-induced death both in p53 -/-and in p53 +/+ thymocytes, indicating a complete dissociation between the BA-and the p53-regulated checkpoints of apoptosis.
Relationship between Apoptotic A vI, r,,, Disruption and Proteases. Different types of proteases have been implicated in the control of apoptosis, at the level of the initial triggering event, as well as at the level of the late effector phase (9) . To determine whether ICE-like proteases might act upstream of PT-mediated Aqrm disruption, thymocytes were exposed to apoptosis inducers such as DEX, etoposide or y-irradiation, in the presence or absence ofprotease inhibitors. The cysteine protease inhibitor Z-VAD.fmk, which acts on ICE-like proteases (23, 24) , prevents both the A~I~ ~ reduction and nuclear apoptosis that are induced by these stimuli (Fig. 4 B) . Similarly, the serine protease inhibitor TLCK inhibits thymocyte apoptosis, as described (25) , and also prevents A~m reduction (Fig. 4 B) . Since TLCK and specific inhibitors of ICE-like proteases and CPP32 do not prevent the mitochondrial release of a proapoptotic factor nor its action on isolated nuclei in a cell-free system (5), it appears that such proteases act upstream rather than downstream of the PT/Bcl-2 control point ofapoptosis.
Concluding Remarks. In the present paper, we demonstrate that the PT-inhibitory substance BA does not only prevent the apoptotic A~ m disruption, but that it also abolishes a number of nuclear, cytoplasmic, and plasma membrane changes that characterize apoptosis. Thus, much as the mitochondrial oncoprotein Bcl-2, BA has an antioxidant effect (in the sense that it prevents glutathione depletion, superoxide anion generation, and NFKB translocation; 26) and inhibits PS exposure on the plasma membrane (19) . These data underline the probable involvement of PT as a critical coordinating event of the apoptotic cascade. Our data also suggest that the BA-inhibitable PT control point is completely independent of p53 and that PT occurs secondary to the activation of certain cysteine and serine proteases. This does not exclude that some proteases are activated downstream of PT. In particular, it appears that the mitochondrial intermembrane factor(s) released upon PT, which cause(s) apoptosis in isolated nuclei, is/are endowed with some protease activity or can activate nuclear proteases. This assumption is based on the observation that several unidentified nuclear proteins become degraded after incubation of isolated nuclei with mitochondrial factor(s) (our unpublished observation). However, it is clear that some critical proteases control a checkpoint upstream of PT, since this is also suggested by the very rapid kinetics of protease activation in some models ofapoptosis (27) . At the present time, little is known about the mechanisms by which biochemical pathways PT is induced in cells that are undergoing apoptosis. Nevertheless, the present study indicates that in addition to protease cascades, mitochondrial PT may fulfill a major role in coordinating the death pathways that invariably accompany late-stage apoptosis.
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